HF
SLXN

HRT Financial’s Silexion Therapeutics SLXN Stock Holding History

HRT Financial’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38K Buy
+15,239
New +$92K ﹤0.01% 3830
2025
Q1 		– Sell
-79
Closed -$23K – 3559
2024
Q4 		$23K Buy
79
+12
+18% +$5.09K ﹤0.01% 2190
2024
Q3 		$47K Buy
+67
New +$105K ﹤0.01% 2117

Other funds holding SLXN

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

HRT Financial's SLXN Position: Q2 2026 in Review

HRT Financial opened a new position in Silexion Therapeutics (SLXN) in Q2 2026: 15,239 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #3830 among its holdings. This is a return to the name: HRT Financial previously reported a position in SLXN as recently as Q4 2024.

HRT Financial first reported a position in SLXN in Q3 2024 and has held it in 3 quarters since. The position peaked at $47K in Q3 2024. 6 funds tracked by Wall St. Rank hold SLXN as of Q2 2026.

  • HRT Financial held 15,239 shares of Silexion Therapeutics worth $38K as of Q2 2026.
  • Silexion Therapeutics was a new HRT Financial position in Q2 2026.
  • Silexion Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3830 holding.
  • HRT Financial first reported a position in Silexion Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • HRT Financial's Silexion Therapeutics position peaked at $47K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.